BRCA2 Recombinant Rabbit mAb,PBS Only (S-5306)

BRCA2 (Breast Cancer Susceptibility Gene 2) is an important tumor suppressor gene, and the protein it encodes plays a central role in maintaining genomic stability, primarily through its involvement in the homologous recombination repair (HRR) pathway to precisely repair DNA double-strand breaks—the most severe form of DNA damage. When DNA double-strand breaks occur in the cell, the BRCA2 protein interacts with multiple key partner molecules, such as the RAD51 recombinase, and through its several internal domains, it precisely loads RAD51 onto single-stranded DNA to form nucleoprotein filaments, thereby guiding homologous sequence search and strand invasion, completing the high-fidelity repair process and ensuring accurate transmission of genetic information. In addition, BRCA2 is involved in cell cycle checkpoint regulation and replication fork protection, preventing replication fork collapse and genomic rearrangements. If pathogenic mutations occur in the BRCA2 gene, its loss of function leads to ineffective DNA damage repair, causing cells to accumulate numerous mutations and significantly increasing the risk of various malignancies, including breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer, with a particularly strong association with early-onset familial breast and ovarian cancers. Clinically, BRCA2 mutation testing is not only used for genetic risk assessment and early screening in high-risk populations, but also provides important guidance for treatment strategy selection. For example, tumors harboring BRCA2 mutations are often more sensitive to PARP inhibitors (such as olaparib) and platinum-based chemotherapy agents, offering a strong basis for targeted therapy and personalized medicine. Meanwhile, the synergistic interactions of BRCA2 with other DNA repair proteins, such as PALB2 and BRCA1, have also made it a hot target in synthetic lethality strategies and combination therapy research, continuously advancing the development of precision oncology.